These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

255 related items for PubMed ID: 10554016

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma.
    Shao JY, Li YH, Gao HY, Wu QL, Cui NJ, Zhang L, Cheng G, Hu LF, Ernberg I, Zeng YX.
    Cancer; 2004 Mar 15; 100(6):1162-70. PubMed ID: 15022282
    [Abstract] [Full Text] [Related]

  • 3. [Quantitative analysis of plasma Epstein-Barr virus (EBV) DNA for monitoring of recurrence and metastasis in nasopharyngeal carcinoma patients after radiotherapy].
    Li YH, Shao JY, Zhao MQ, Gao HY, Li LR, Guan ZZ, Zeng YX.
    Ai Zheng; 2003 Jun 15; 22(6):645-8. PubMed ID: 12948418
    [Abstract] [Full Text] [Related]

  • 4. [Significance of cell-free Epstein-Barr virus DNA in monitoring prognosis of nasopharyngeal carcinoma].
    Cao SM, Min HQ, Gao JS, Hong MH, Xiao XB, Zhang CQ, Liu XD, Zhang AL, Guo X.
    Ai Zheng; 2003 Mar 15; 22(3):302-6. PubMed ID: 12654192
    [Abstract] [Full Text] [Related]

  • 5. Long-term prognostic effects of plasma epstein-barr virus DNA by minor groove binder-probe real-time quantitative PCR on nasopharyngeal carcinoma patients receiving concurrent chemoradiotherapy.
    Lin JC, Wang WY, Liang WM, Chou HY, Jan JS, Jiang RS, Wang JY, Twu CW, Liang KL, Chao J, Shen WC.
    Int J Radiat Oncol Biol Phys; 2007 Aug 01; 68(5):1342-8. PubMed ID: 17449194
    [Abstract] [Full Text] [Related]

  • 6. Comparison of clinical and molecular surveillance in patients with advanced nasopharyngeal carcinoma after primary therapy: the potential role of quantitative analysis of circulating Epstein-Barr virus DNA.
    Hong RL, Lin CY, Ting LL, Ko JY, Hsu MM.
    Cancer; 2004 Apr 01; 100(7):1429-37. PubMed ID: 15042677
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Pretherapy quantitative measurement of circulating Epstein-Barr virus DNA is predictive of posttherapy distant failure in patients with early-stage nasopharyngeal carcinoma of undifferentiated type.
    Leung SF, Chan AT, Zee B, Ma B, Chan LY, Johnson PJ, Lo YM.
    Cancer; 2003 Jul 15; 98(2):288-91. PubMed ID: 12872347
    [Abstract] [Full Text] [Related]

  • 10. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma.
    Lin JC, Wang WY, Chen KY, Wei YH, Liang WM, Jan JS, Jiang RS.
    N Engl J Med; 2004 Jun 10; 350(24):2461-70. PubMed ID: 15190138
    [Abstract] [Full Text] [Related]

  • 11. Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma.
    Lo YM, Chan LY, Lo KW, Leung SF, Zhang J, Chan AT, Lee JC, Hjelm NM, Johnson PJ, Huang DP.
    Cancer Res; 1999 Mar 15; 59(6):1188-91. PubMed ID: 10096545
    [Abstract] [Full Text] [Related]

  • 12. [Prognostic impact of plasma Epstein-Barr virus DNA concentration on distant metastasis in nasopharyngeal carcinoma].
    Hou X, Zhang L, Zhao C, Li S, Lu LX, Han F, Shao JY, Huang PY.
    Ai Zheng; 2006 Jul 15; 25(7):785-92. PubMed ID: 16831265
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A comparison study of different PCR assays in measuring circulating plasma epstein-barr virus DNA levels in patients with nasopharyngeal carcinoma.
    Le QT, Jones CD, Yau TK, Shirazi HA, Wong PH, Thomas EN, Patterson BK, Lee AW, Zehnder JL.
    Clin Cancer Res; 2005 Aug 15; 11(16):5700-7. PubMed ID: 16115906
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Plasma Epstein-Barr virus DNA screening followed by ¹⁸F-fluoro-2-deoxy-D-glucose positron emission tomography in detecting posttreatment failures of nasopharyngeal carcinoma.
    Wang WY, Twu CW, Lin WY, Jiang RS, Liang KL, Chen KW, Wu CT, Shih YT, Lin JC.
    Cancer; 2011 Oct 01; 117(19):4452-9. PubMed ID: 21437892
    [Abstract] [Full Text] [Related]

  • 20. Rapid clearance of plasma Epstein-Barr virus DNA after surgical treatment of nasopharyngeal carcinoma.
    To EW, Chan KC, Leung SF, Chan LY, To KF, Chan AT, Johnson PJ, Lo YM.
    Clin Cancer Res; 2003 Aug 15; 9(9):3254-9. PubMed ID: 12960110
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.